Zocilurtatug pelitecan showed an overall response rate of 38.2% and a disease control rate of 55.9% in 34 patients with pretreated extrapulmonary neuroendocrine carcinomas. Grade 3 or higher treatment-emergent adverse effects occurred in 30.4% of patients.
Yale Cancer Center experts presented research at the 2026 AACR Annual Meeting in San Diego, including patient-centered trials, pathology methods and head and neck cancer studies. The meeting also included a plenary presentation, a pathology award and an AACR Trailblazer Cancer Research Grant.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07006727 |
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors |
RECRUITING | PHASE1 |
